ASLAN Pharmaceuticals to Present New Data on ASLAN003 at American Society of Hematology Annual Meeting
ASLAN003 is an orally active, potent inhibitor of Dihydroorotate Dehydrogenase (DHODH) that has the potential to be first-in-class in acute myeloid leukaemia (AML). In previous clinical studies, ASLAN003 has demonstrated potent inhibition of DHODH (up to two orders of magnitude stronger than first generation DHODH inhibitors), lack of toxicities associated with first generation inhibitors and other novel AML therapies, and the potential to induce differentiation in blast cells and applicability in a broad range of AML patients.
ASLAN will present preliminary results from an ongoing multicentre, single arm phase 2a dose optimisation study of ASLAN003 in AML patients who are ineligible for standard therapy.
In a second poster, new data from a preclinical study evaluating the effects of ASLAN003 on cell growth, differentiation, apoptosis, and gene expression changes in AML cell lines and primary bone marrow cells from patients with AML will be presented.
Details of the accepted abstracts are listed below and are now available online on the ASH conference website: http://www.hematology.org/Annual-Meeting/Abstracts/.
Poster Number: 2676
Abstract Title: Preliminary Results of a Phase 2a Dose Optimization Study of ASLAN003 (DHODH inhibitor) in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible for Standard Therapy; Early Signs of Activity
Session Title: 613. Acute Myeloid Leukemia: Clinical Studies: Poster II
Date/Time:
Location:
Poster Number: 4047
Abstract Title: ASLAN003, a Novel and Potent Dihydroorotate Dehydrogenase (DHODH) Inhibitor, Induces Differentiation of Acute Myeloid Leukemia
Session Title: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III
Date/Time:
Location: San Diego Convention Center, Hall GH
Media and IR contacts
Emma Thompson Spurwing Communications Tel: +65 6340 7287 Email: ASLAN@spurwingcomms.com |
Robert Uhl Westwicke Partners Tel: +1 858 356 5932 Email: robert.uhl@westwicke.com |
About ASLAN003
ASLAN003 is an orally active, potent inhibitor of DHODH that has the potential to be first-in-class in acute myeloid leukaemia (AML). Licensed from
About
Forward looking statements
This release and the accompanying financial information, if any, contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of
All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.
Source: ASLAN Pharmaceuticals Limited